Clinical Trials Browser

Phase 2 × trilaciclib × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06027268 2026-02-03

ToPCourT

Phase 2 Active not recruiting

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06370416 2026-01-28

the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

Phase 2 Enrolling by invitation

Carcinoma, Non-Small-Cell Lung

NCT03041311 2025-09-25

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

Phase 2 Completed

107 enrolled 42 charts

Small Cell Lung Carcinoma

NCT04887831 2025-09-08

PRESERVE3

Phase 2 Terminated

92 enrolled 24 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05578326 2025-07-08

Study of Trilaciclib and Lurbinectidin

Phase 2 Recruiting

Lung Neoplasms, Neutropenia, Small Cell Lung Carcinoma

NCT06992739 2025-05-28

PROTECT-2

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06955156 2025-05-02

Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT05113966 2025-01-29

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Phase 2 Terminated

30 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT06752798 2024-12-31

CCRT，LA-HNSCC

Phase 2 Recruiting

Head and Neck Neoplasms

NCT06714266 2024-12-03

Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06699472 2024-11-21

A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib

Phase 2 Recruiting

Sarcoma, Ewing

NCT06490081 2024-09-24

Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

Phase 2 Recruiting

Myelosuppression

NCT06569459 2024-08-26

Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer

Phase 2 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT06328049 2024-03-25

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC

Phase 2 Recruiting

NSCLC

NCT06297811 2024-03-07

Myeloprotection With Trilaciclib in Pan-cancer Population

Phase 2 Not yet recruiting

BreastGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT06217003 2024-01-22

Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma

Phase 2 Unknown

Osteosarcoma

NCT05978648 2023-11-30

SMA-BC-002

Phase 2 Recruiting

Breast Neoplasms

NCT05862610 2023-07-24

The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC

Phase 2 Not yet recruiting

Breast Neoplasms

NCT05900921 2023-06-13

Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

Phase 2 Unknown

Advanced Squamous Non-Small-Cell Lung Cancer

NCT04863248 2023-04-14

PRESERVE 4

Phase 2 Terminated

10 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT02978716 2022-03-23

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

Phase 2 Terminated

102 enrolled 51 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms